Search results
Results From The WOW.Com Content Network
Detect prostate cancer (when no symptoms are present) Prostate cancer screening is the screening process used to detect undiagnosed prostate cancer in men without signs or symptoms. [ 1][ 2] When abnormal prostate tissue or cancer is found early, it may be easier to treat and cure, but it is unclear if early detection reduces mortality rates ...
Prostate cancer is a major topic of ongoing research. From 2016–2020, over $1.26 billion was invested in prostate cancer research, representing around 5% of global cancer research funds. [121] This places prostate cancer 10th among 18 common cancer types in funding per cancer death, and 9th in funding per disability-adjusted life year lost. [122]
A PSMA scan is a nuclear medicine imaging technique used in the diagnosis and staging of prostate cancer. It is carried out by injection of a radiopharmaceutical with a positron or gamma emitting radionuclide and a prostate-specific membrane antigen (PSMA) targeting ligand. After injection, imaging of positron emitters such as gallium-68 ( 68 ...
A biomarker may be a molecule secreted by a tumor or a specific response of the body to the presence of cancer. Genetic, [1] epigenetic, [2] proteomic, [3] glycomic, [4] and imaging biomarkers can be used for cancer diagnosis, prognosis, and epidemiology. Ideally, such biomarkers can be assayed in non-invasively collected biofluids like blood ...
Prostate-specific antigen (PSA, also known as kallikrein III, seminin, semenogelase, γ-seminoprotein and P-30 antigen) is a 34- kD glycoprotein produced almost exclusively by the prostate gland. It is a serine protease ( EC 3.4.21.77) enzyme, the gene of which is located on the 19th chromosome (19q13) in humans. [ 28]
Treatment for prostate cancer may involve active surveillance, surgery, radiation therapy – including brachytherapy ( prostate brachytherapy) and external-beam radiation therapy, proton therapy, high-intensity focused ultrasound (HIFU), cryosurgery, hormonal therapy, chemotherapy, or some combination. Treatments also extend to survivorship ...
Early prostate cancer antigen-2. Early prostate cancer antigen-2 ( EPCA-2) is a protein of which blood levels are elevated in prostate cancer. It appears to provide more accuracy in identifying early prostate cancer than the standard prostate cancer marker, PSA . "EPCA-2" is not the name of a gene. EPCA-2 gets its name because it is the second ...
PCA3. Prostate cancer antigen 3 ( PCA3, also referred to as DD3) is a gene that expresses a non-coding RNA. PCA3 is only expressed in human prostate tissue, and the gene is highly overexpressed in prostate cancer. [3] [4] Because of its restricted expression profile, the PCA3 RNA is useful as a tumor marker. [5]